AMENDMENT TO THE CLAIMS

1. (original) A compound of the formula:



Formula I

wherein R^1 is hydrogen or $(C_1\text{-}C_6)$ alkyl;

R^2 is selected from the group consisting of:


, 
, or 
;

R^3 is $(C_1\text{-}C_6)$alkyl, or $(CH_2)_nX$;

R^4 is $(C_1\text{-}C_6)$alkyl, or $(CH_2)_nX$;

R^5 is hydrogen, $(C_1\text{-}C_6)$alkyl, or $(CH_2)_nX$;

X is selected from the group consisiting of a halogen, NR^aR^b,
N-morpholino, N-piperidine, N-pyrrolidine, or N-azepane;
n is an integer from 1-4;
m is an integer from 1-3;

R^a and R^b are each independently hydrogen or $(C_1\text{-}C_6)$alkyl;
and the pharmaceutically acceptable salts thereof.

2. (original) A compound according to Claim 1 wherein:
R^1 is hydrogen or $(C_1\text{-}C_6)$ alkyl;
R^2 is



;

R^3 is $(C_1\text{-}C_6)$alkyl, or $(CH_2)_nX$;
X is selected from the group consisiting of a halogen, NR^aR^b,
N-morpholino, N-piperidine, N-pyrrolidine, or N-azepane;
n is an integer from 1-4;
m is an integer from 1-3;
R^a and R^b are each independently hydrogen or $(C_1\text{-}C_6)$alkyl;
and the pharmaceutically acceptable salts thereof.

3. (original) A compound according to Claim 1 wherein:
R^1 is hydrogen or $(C_1\text{-}C_6)$ alkyl;
R^2 is



;

R^4 is $(C_1\text{-}C_6)$alkyl, or $(CH_2)_nX$;
X is selected from the group consisiting of a halogen, NR^aR^b,
N-morpholino, N-piperidine, N-pyrrolidine, or N-azepane;
n is an integer from 1-4;
m is an integer from 1-3;

R^a and R^b are each independently hydrogen or $(C_1$-$C_6)$alkyl;
and the pharmaceutically acceptable salts thereof.

4. (original) A compound according to Claim 1 wherein:
R^1 is hydrogen or $(C_1$-$C_6)$ alkyl;
R^2 is



;

R^5 is hydrogen, $(C_1$-$C_6)$alkyl, or $(CH_2)_nX$;
X is selected from the group consisiting of a halogen, NR^aR^b,
N-morpholino, N-piperidine, N-pyrrolidine, or N-azepane;
n is an integer from 1-4;
m is an integer from 1-3;
R^a and R^b are each independently hydrogen or $(C_1$-$C_6)$alkyl;
and the pharmaceutically acceptable salts thereof.

5. (currently amended) A compound according to ~~Claims 1 to 4~~ Claim 1 wherein m is 1.

6. (currently amended) A compound according to ~~Claims 1 to 5~~ Claim 1 wherein R^3 is methyl.

7. (currently amended) A compound according to ~~Claims 1 to 6~~ Claim 1 wherein R^1 is methyl.

8. (currently amended) A pharmaceutical formulation comprising a compound according to ~~any one of Claims 1 to 7~~ Claim 1 in combination with a pharmaceutically acceptable diluent, excipient or carrier.

9. (currently amended) A method of treating susceptible neoplasms in a patient in need thereof which comprises administering to said patient a therapeutically effective amount of a compound according to ~~any one of Claims 1 to 7~~ Claim 1.

10. (currently amended) A method of treating fibrosis in a patient in need thereof which comprises administering to said patient a therapeutically effective amount of a compound according to ~~any one of Claims 1 to 7~~ Claim 1.